Cardiology in Review最新文献_第10页

Acute Myocardial Infarction in Pregnancy. 妊娠期急性心肌梗死。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-27 DOI: 10.1097/CRD.0000000000000681

Jitae A Kim, Sophie Y Kim, Hafeez Ul Hassan Virk, Mahboob Alam, Samin Sharma, Mark R Johnson, Chayakrit Krittanawong

引用次数: 0

Renal Congestion in Heart Failure: Insights in Novel Diagnostic Modalities. 心力衰竭的肾脏充血：新诊断模式的启示。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-29 DOI: 10.1097/CRD.0000000000000673

Kyriakos Dimitriadis, Aikaterini Damianaki, Evanthia Bletsa, Nikolaos Pyrpyris, Panagiotis Tsioufis, Panagiotis Theofilis, Eirini Beneki, Fotis Tatakis, Alexandros Kasiakogias, Evangelos Oikonomou, Dimitrios Petras, Gerasimos Siasos, Konstantina Aggeli, Konstantinos Tsioufis

{"title":"Renal Congestion in Heart Failure: Insights in Novel Diagnostic Modalities.","authors":"Kyriakos Dimitriadis, Aikaterini Damianaki, Evanthia Bletsa, Nikolaos Pyrpyris, Panagiotis Tsioufis, Panagiotis Theofilis, Eirini Beneki, Fotis Tatakis, Alexandros Kasiakogias, Evangelos Oikonomou, Dimitrios Petras, Gerasimos Siasos, Konstantina Aggeli, Konstantinos Tsioufis","doi":"10.1097/CRD.0000000000000673","DOIUrl":"10.1097/CRD.0000000000000673","url":null,"abstract":"Heart failure is increasingly prevalent and is estimated to increase its burden in the following years. A well-reported comorbidity of heart failure is renal dysfunction, where predominantly changes in the patient's volume status, tubular necrosis or other mechanical and neurohormonal mechanisms seem to drive this impairment. Currently, there are established biomarkers evaluating the patient's clinical status solely regarding the cardiovascular or renal system. However, as the coexistence of heart and renal failure is common and related to increased mortality and hospitalization for heart failure, it is of major importance to establish novel diagnostic techniques, which could identify patients with or at risk for cardiorenal syndrome and assist in selecting the appropriate management for these patients. Such techniques include biomarkers and imaging. In regards to biomarkers, several peptides and miRNAs indicative of renal or tubular dysfunction seem to properly identify patients with cardiorenal syndrome early on in the course of the disease, while changes in their serum levels can also be helpful in identifying response to diuretic treatment. Current and novel imaging techniques can also identify heart failure patients with early renal insufficiency and assess the volume status and the effect of treatment of each patient. Furthermore, by assessing the renal morphology, these techniques could also help identify those at risk of kidney impairment. This review aims to present all relevant clinical and trial data available in order to provide an up-to-date summary of the modalities available to properly assess cardiorenal syndrome.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"163-174"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139995728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fontan-Associated Liver Disease: A Review. 丰坦相关肝病：综述。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-03-13 DOI: 10.1097/CRD.0000000000000684

Gabriel Heering, Nachum Lebovics, Raksheeth Agarwal, William H Frishman, Edward Lebovics

{"title":"Fontan-Associated Liver Disease: A Review.","authors":"Gabriel Heering, Nachum Lebovics, Raksheeth Agarwal, William H Frishman, Edward Lebovics","doi":"10.1097/CRD.0000000000000684","DOIUrl":"10.1097/CRD.0000000000000684","url":null,"abstract":"Fontan-associated liver disease (FALD) is a chronic complication of the Fontan procedure, a palliative surgery for patients with congenital heart disease that results in a single-ventricle circulation. The success of the Fontan procedure has led to a growing population of post-Fontan patients living well into adulthood. For this population, FALD is a major cause of morbidity and mortality. It encompasses a spectrum of hepatic abnormalities, ranging from mild fibrosis to cirrhosis and hepatocellular carcinoma. The pathophysiology of FALD is multifactorial, involving hemodynamic and inflammatory factors. The diagnosis and monitoring of FALD present many challenges. Conventional noninvasive tests that use liver stiffness as a surrogate marker of fibrosis are unreliable in FALD, where liver stiffness is also a result of congestion due to the Fontan circulation. Even invasive tissue sampling is inconsistent due to the patchy distribution of fibrosis. FALD is also associated with both benign and malignant liver lesions, which may exhibit similar imaging features. There is therefore a need for validated diagnostic and surveillance protocols to address these challenges. The definitive treatment of end-stage FALD is also a subject of controversy. Both isolated heart transplantation and combined heart-liver transplantation have been employed, with the latter becoming increasingly preferred in the US. This article reviews the current literature on the epidemiology, pathophysiology, diagnosis, and management of FALD, and highlights knowledge gaps that require further research.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"152-162"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Personalized Cell-Based Therapy for Ischemic Heart Failure With Reduced Ejection Fraction: Safety and Feasibility Outcomes of the Roll-In Cohort of the CardiAMP Cell Therapy Trial and Review of Similar Trials. 针对射血分数降低的缺血性心力衰竭的个性化细胞疗法：CardiAMP细胞疗法试验滚动队列的安全性和可行性结果及类似试验回顾。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-16 DOI: 10.1097/CRD.0000000000000659

Jared M Feldman, William H Frishman, Wilbert S Aronow

{"title":"A Personalized Cell-Based Therapy for Ischemic Heart Failure With Reduced Ejection Fraction: Safety and Feasibility Outcomes of the Roll-In Cohort of the CardiAMP Cell Therapy Trial and Review of Similar Trials.","authors":"Jared M Feldman, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000659","DOIUrl":"10.1097/CRD.0000000000000659","url":null,"abstract":"CardiAMP Cell Therapy for Heart Failure trial is a prospective, multicenter, randomized, controlled, double-blinded trial that has been granted breakthrough designation by the United States Food and Drug Administration. This trial evaluates clinical outcomes of intramyocardial delivery of a high dose of autologous bone marrow mononuclear cells in chronic postmyocardial infarction heart failure patients. This trial represents the first attempt to personalize marrow-derived cell-based therapy for the treatment of ischemic heart failure with reduced ejection fraction. The roll-in cohort of 10 patients demonstrated improvements in 6-minute walk distance at 6 months (+47.8 m, P = 0.01), 12 months (+46.4 m, P = 0.06), and 24 months (+31 m), and improvements in New York Heart Association class at 3 months ( P = 0.015) and 6 months ( P = 0.037). Four patients were reduced to New York Heart Association class I at 24 months and Minnesota Living with Heart Failure Questionnaire score was improved in 6 of 10 patients at 24 months. The improved clinical outcomes demonstrated in CardiAMP are consistent with previous clinical trials including the Transendocardial Autologous Cells in Ischemic Heart Failure (TAC-HFT) trial, Prospective Randomized Trial of Direct Endomyocardial Implantation of Bone Marrow Cells for Treatment of Severe Coronary Artery Diseases (PROTECT-CAD), and REGENERATE-Ischemic Heart Disease trial.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"130-133"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Rising Use of E-Cigarettes: Unveiling the Health Risks and Controversies. 电子烟的使用日益增多：揭开健康风险和争议的面纱。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-22 DOI: 10.1097/CRD.0000000000000666

Parth Sheth, Fena Mehta, Gurusha Jangid, F N U Anamika, Bhupinder Singh, Sai Gautham Kanagala, Rohit Jain

{"title":"The Rising Use of E-Cigarettes: Unveiling the Health Risks and Controversies.","authors":"Parth Sheth, Fena Mehta, Gurusha Jangid, F N U Anamika, Bhupinder Singh, Sai Gautham Kanagala, Rohit Jain","doi":"10.1097/CRD.0000000000000666","DOIUrl":"10.1097/CRD.0000000000000666","url":null,"abstract":"The use of e-cigarettes has tremendously increased in recent times due to the widespread availability of e-cigarettes in diverse flavors, reduced cost compared to regular cigarettes, and misconception of being comparatively safe, which have led to around 2.55 million US middle and high school students smoking e-cigarettes. These devices use a nicotine-rich liquid, which is aerosolized electronically, producing vapors that may also include hazardous chemicals and heavy metals. E-cigarettes are associated with e-cigarette or vaping-associated lung injury, which presents as an acute respiratory ailment mirroring various pulmonary diseases. Additionally, it causes endothelial dysfunction, alters blood lipid profile by elevating circulating levels of low-density lipoprotein cholesterol, increases sympathetic tone, and is found to correlate with arterial stiffening, hence negatively affecting respiratory, cardiovascular, and overall health. We aim to provide a comprehensive analysis of the data on e-cigarettes and their harmful effects on health in comparison to conventional cigarette use by highlighting the pathophysiology of e-cigarette-induced adverse effects and critically analyzing the data both in favor and against its use. Our review concludes that no matter how much nicotine an e-cigarette contains, evidence shows that using it increases the risk of cardiovascular disease, albeit maybe not as much as smoking regular tobacco. Nonetheless, it is crucial to note that the long-term effects of e-cigarette usage are still not fully understood, and existing data have provided opposing viewpoints.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"117-122"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harmonizing Hearts: Exploring the Impact of Music Therapy on Cardiovascular Health. 和谐心灵：探索音乐疗法对心血管健康的影响。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-03-05 DOI: 10.1097/CRD.0000000000000676

Bhargav Sai Nuthalapati, Debankur Dey, Bhupinder Singh, F N U Anamika, Sai Gautham Kanagala, Nikita Garg, Rohit Jain

{"title":"Harmonizing Hearts: Exploring the Impact of Music Therapy on Cardiovascular Health.","authors":"Bhargav Sai Nuthalapati, Debankur Dey, Bhupinder Singh, F N U Anamika, Sai Gautham Kanagala, Nikita Garg, Rohit Jain","doi":"10.1097/CRD.0000000000000676","DOIUrl":"10.1097/CRD.0000000000000676","url":null,"abstract":"Music therapy (MT) is a music intervention involving a credentialed professional and a client, which has gained increasing recognition in current practices as an adjunct therapy for various conditions, including cardiovascular diseases (CVDs). MT demonstrates notable physiological as well as psychological effects leading to lowered anxiety, depression, and systolic blood pressure in patients with CVDs as well as having effects on heart rate and heart rate variability in healthy subjects. MT emerges as a promising adjunct in the prevention and rehabilitation of CVDs and its holistic impact on physiological and psychological parameters underscores its potential as a noninvasive, cost-effective intervention. Existing literature shows heterogeneity in methods in the studies such as the genre and quality of music utilized as well outcomes. While further research is warranted to optimize protocols and assess long-term effects, the current evidence highlights MT's substantial benefits in cardiovascular health care, making it a promising asset in modern therapeutic approaches. This comprehensive review explores the multifaceted role of MT in CVDs, discussing its mechanisms and clinical applications.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"138-143"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transvenous Compared With Leadless Pacemakers: A meta-analysis comparing TP versus LP. 经静脉起搏器与无引线起搏器的比较：经静脉起搏器与无引线起搏器的荟萃分析。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-01 DOI: 10.1097/CRD.0000000000000660

Shady Habboush, Ahmed Elmoursi, Ahmed F Gadelmawla, Amr T Masoud, Mohamed Khalil, Hesham Sheashaa, Nooraldin Merza, Ahmed T Massoud

{"title":"Transvenous Compared With Leadless Pacemakers: A meta-analysis comparing TP versus LP.","authors":"Shady Habboush, Ahmed Elmoursi, Ahmed F Gadelmawla, Amr T Masoud, Mohamed Khalil, Hesham Sheashaa, Nooraldin Merza, Ahmed T Massoud","doi":"10.1097/CRD.0000000000000660","DOIUrl":"10.1097/CRD.0000000000000660","url":null,"abstract":"This study aims to compare the effectiveness of leadless pacemakers (LPs) and transvenous pacemakers and to examine the safety of both methods. We included patients undergoing single-chamber pacemaker implantation, either LP or TVP. Our outcomes were successful implantation rate, major complication, vascular injury, tamponade, and pneumothorax. We performed a double-arm analysis comparing LP versus TVP, with risk ratio (RR) and 95% confidence interval. A total of 10 studies were included in this meta-analysis. Regarding efficacy endpoints, RR revealed no significant difference between the LP and transvenous pacemaker groups in terms of successful rate of implantation (RR = 1.00; P = 0.77). Regarding safety outcomes, LP experienced lower incidence of major complications (RR = 0.47; P = 0.01), infection (RR = 0.24; P = 0.001), and tamponade (RR = 0.36; P = 0.01). There was no significant difference between both groups regarding pneumothorax (RR = 0.35; P = 0.22) and vascular injury (RR = 1.55; P = 0.25). The study findings suggest that both LPs and TVPs have similar effectiveness. Moreover, the incidences of pneumothorax, vascular injuries, and major complications were found to be comparable between the 2 methods. However, LPs were found to have lower rates of infection and tamponade.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"123-129"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Image and Clinical Characteristics of the Right Coronary Artery Originating From the Left Coronary Sinus: A Database Review. 源自左冠状动脉窦的右冠状动脉的图像和临床特征：数据库回顾。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-02-16 DOI: 10.1097/CRD.0000000000000669

Mingyuan Yuan, Jiani Zhang

引用次数: 0

Epicardial Adipose Tissue: A Precise Biomarker for Cardiovascular Risk, Metabolic Diseases, and Target for Therapeutic Interventions. 心外膜脂肪组织：心外膜脂肪组织：心血管风险、代谢性疾病的精确生物标志物和治疗干预的靶点

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-03-13 DOI: 10.1097/CRD.0000000000000670

Aleksander Bogdański, Piotr Niziołek, Stanisław Kopeć, Małgorzata Moszak

{"title":"Epicardial Adipose Tissue: A Precise Biomarker for Cardiovascular Risk, Metabolic Diseases, and Target for Therapeutic Interventions.","authors":"Aleksander Bogdański, Piotr Niziołek, Stanisław Kopeć, Małgorzata Moszak","doi":"10.1097/CRD.0000000000000670","DOIUrl":"10.1097/CRD.0000000000000670","url":null,"abstract":"Epicardial adipose tissue (EAT) is located between the heart muscle and visceral pericardium, where it has direct contact with coronary blood vessels. Elevated thickness of this tissue can induce local inflammation affecting the myocardium and the underlying coronary arteries, contributing to various cardiovascular diseases such as coronary artery disease, atrial fibrillation, or heart failure with preserved ejection fraction. Recent studies have identified EAT thickness as a simple and reliable biomarker for certain cardiovascular outcomes. Examples include the presence of atherosclerosis, incident cardiovascular disease (CVD) in individuals with type 2 diabetes mellitus (T2DM), and the prevalence of atrial fibrillation. Furthermore, EAT measurements can help to identify patients with a higher risk of developing metabolic syndrome. Since the EAT thickness can be easily measured using echocardiography, such examinations could serve as a useful and cost-effective preventive tool for assessing cardiovascular health. This review also summarizes therapeutical interventions aimed at reducing EAT. Reducing EAT thickness has been shown to be possible through pharmacological, surgical, or lifestyle-change interventions. Pharmaceutical therapies, including thiazolidinediones, glucagon-like peptide 1-receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and statins, have been shown to influence EAT thickness. Additionally, EAT thickness can also be managed more invasively through bariatric surgery, or noninvasively through lifestyle changes to diet and exercise routines.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"97-106"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140109285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining the Role of Cerebral Embolic Protection Devices in Preventing Postoperative Stroke in Patients with a History of Stroke or Transient Ischemic: Insights from the National Inpatient Sample. 研究脑栓塞保护装置在预防有中风或短暂性脑缺血病史患者术后中风中的作用：来自全国住院患者样本的启示。

IF 2.3 4区医学

Cardiology in Review Pub Date : 2026-03-01 Epub Date: 2024-03-04 DOI: 10.1097/CRD.0000000000000674

Rupak Desai, Avilash Mondal, Nishanth Katukuri, Adhvithi Pingili, Vamsikalyan Borra, Parth R Nayak, Akhil Jain, Harshil Patel, Omar Qaqish, Ankit Vyas, Ashok Kondur

{"title":"Examining the Role of Cerebral Embolic Protection Devices in Preventing Postoperative Stroke in Patients with a History of Stroke or Transient Ischemic: Insights from the National Inpatient Sample.","authors":"Rupak Desai, Avilash Mondal, Nishanth Katukuri, Adhvithi Pingili, Vamsikalyan Borra, Parth R Nayak, Akhil Jain, Harshil Patel, Omar Qaqish, Ankit Vyas, Ashok Kondur","doi":"10.1097/CRD.0000000000000674","DOIUrl":"10.1097/CRD.0000000000000674","url":null,"abstract":"Cerebral embolic protection devices (CEPD) during transcatheter aortic valve replacement (TAVR) have been shown to lower the risk of stroke during the procedure. However, their long-term and clinical effects on neuro-cognition are unknown. Therefore, we hypothesized the benefit of CEPD in TAVR patients with a prior history of stroke or transient ischemic attack (TIA). National Inpatient Sample (2019) and International Classification of Diseases, 10th Revision codes were used to identify patients undergoing TAVR with prior stroke or TIA. Propensity-matched analysis was performed to adjust for baseline characteristics and comorbidities. Primary outcome measures were postoperative stroke and all-cause mortality. Length of stay and hospital cost were secondary outcomes. Of 8450 unmatched TAVR patients with prior stroke or TIA in 2019, 1095 (13%) utilized CEPD. After propensity matching previous myocardial infarction (MI), coronary artery bypass grafting, and drug abuse were higher in the TAVR-only cohort. Postoperative stroke rate (1.4% vs 2.2%; P = 0.081) and odds [adjusted odds ratio (aOR), 0.48; 95% confidence interval (CI), 0.11-2.17; P = 0.341] were lower in the CEPD group. There was no difference in all-cause in-hospital mortality between the 2 groups (0.9% vs 1.0%). Length of stay (3 vs 2 days, P <0.001) and hospital expenditure ($172,711 vs $162,284; P = 0.002) were higher for the TAVR-only cohort. CEPD in TAVR patients with prior stroke or TIA did not show statistically significant postoperative stroke benefits. However, further larger-scale prospective studies are needed to evaluate the long-term neurocognitive benefits of CEPD in these patients. As the use of TAVR continues to expand, optimizing peri-procedural strategies such as the use of CEPD remains a critical area of research to improve patient outcomes.","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"134-137"},"PeriodicalIF":2.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140020973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0